Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTBL NASDAQ:TLPH NASDAQ:TRAW NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTBLNotable Labs$0.25$0.33$0.22▼$4.24$2.24M0.981.01 million shs2.11 million shsTLPHTalphera$0.41-4.7%$0.48$0.38▼$1.19$8.82M-0.11138,010 shs205,967 shsTRAWTraws Pharma$1.60-1.2%$1.49$0.97▼$19.44$9.01M1.46451,723 shs46,560 shsXFORX4 Pharmaceuticals$1.43-4.0%$2.67$1.38▼$26.96$8.63M0.54169,404 shs1.21 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTBLNotable Labs0.00%0.00%0.00%0.00%-64.59%TLPHTalphera-4.67%-21.17%-15.83%-14.78%-55.45%TRAWTraws Pharma-1.23%+5.26%-3.03%-19.19%+159,999,900.00%XFORX4 Pharmaceuticals-4.03%0.00%-49.29%-75.02%-93.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNTBLNotable LabsN/AN/AN/AN/AN/AN/AN/AN/ATLPHTalphera2.4199 of 5 stars3.82.00.00.03.30.00.6TRAWTraws Pharma0.3603 of 5 stars0.05.00.00.00.00.80.0XFORX4 Pharmaceuticals4.7945 of 5 stars3.54.00.04.60.63.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTBLNotable Labs 2.00HoldN/AN/ATLPHTalphera 3.50Strong Buy$5.001,119.81% UpsideTRAWTraws Pharma 0.00N/AN/AN/AXFORX4 Pharmaceuticals 3.00Buy$72.334,958.28% UpsideCurrent Analyst Ratings BreakdownLatest NTBL, TLPH, XFOR, and TRAW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $7.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTBLNotable Labs$313K7.14N/AN/A$6.81 per share0.04TLPHTalphera$650K12.93N/AN/A$0.47 per share0.87TRAWTraws Pharma$230K38.68N/AN/A($8.66) per share-0.18XFORX4 Pharmaceuticals$2.56M3.23N/AN/A$3.90 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTBLNotable Labs-$11.26MN/A0.00∞N/AN/A-80.81%-62.86%N/ATLPHTalphera-$13M-$0.45N/AN/AN/AN/A-130.28%-59.25%8/13/2025 (Estimated)TRAWTraws Pharma-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)XFORX4 Pharmaceuticals-$37.45M$2.140.67N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)Latest NTBL, TLPH, XFOR, and TRAW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025XFORX4 Pharmaceuticals-$4.53N/AN/AN/AN/AN/A8/13/2025Q2 2025TLPHTalphera-$0.1150N/AN/AN/AN/AN/A5/15/2025Q1 2025TRAWTraws Pharma-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million5/1/2025Q1 2025XFORX4 Pharmaceuticals-$4.13$0.04+$4.17$0.04$7.03 million$28.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNTBLNotable LabsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTBLNotable Labs0.032.772.77TLPHTalpheraN/A3.113.11TRAWTraws PharmaN/A1.811.81XFORX4 Pharmaceuticals3.303.703.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTBLNotable Labs70.48%TLPHTalphera37.67%TRAWTraws Pharma7.95%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipNTBLNotable Labs1.20%TLPHTalphera3.20%TRAWTraws Pharma13.60%XFORX4 Pharmaceuticals2.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTBLNotable Labs409.02 million9.54 millionNo DataTLPHTalphera1920.50 million19.85 millionOptionableTRAWTraws Pharma175.56 million4.81 millionOptionableXFORX4 Pharmaceuticals805.79 million5.65 millionOptionableNTBL, TLPH, XFOR, and TRAW HeadlinesRecent News About These CompaniesX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?July 10, 2025 | americanbankingnews.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 10, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comX4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA CongressMay 16, 2025 | nasdaq.comX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14, 2025 | globenewswire.comX4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 2, 2025 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comX4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | finance.yahoo.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | globenewswire.comX4 Pharmaceuticals Q1 2025 Earnings PreviewApril 30, 2025 | msn.comX4 Pharmaceuticals Analyst RatingsApril 30, 2025 | benzinga.comEarnings Preview For X4 PharmaceuticalsApril 30, 2025 | benzinga.comWhy X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025April 30, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTBL, TLPH, XFOR, and TRAW Company DescriptionsNotable Labs NASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.Talphera NASDAQ:TLPH$0.41 -0.02 (-4.67%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.42 +0.01 (+1.73%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.Traws Pharma NASDAQ:TRAW$1.60 -0.02 (-1.23%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.61 +0.01 (+0.56%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.X4 Pharmaceuticals NASDAQ:XFOR$1.43 -0.06 (-4.03%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.42 -0.01 (-0.70%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
